Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company

September 19, 2016 1:37 PM EDT
Get Alerts SRPT Hot Sheet
Price: $47.98 -2.18%

Rating Summary:
    16 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Needham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $81.00 (from $47.00) following eteplirsen approval.

Messer commented, "The FDA has granted conditional approval to eteplirsen (Exondys 51) stating that data on dystrophin production was "reasonably likely to predict clinical benefit". We conclude from this statement that the Western blots from the 1st 13 PROMOVI subjects must have been convincing, which bodes well for the study as a whole as well as for the ongoing ESSENCE study. While the FDA approval letter to Sarepta contains some additional post approval requirements beyond our expectations, the prospect of commercial sales beginning shortly more than mitigates the added expense. While the regulatory saga at Sarepta may be over, we think the company's story as drug developers in DMD is just beginning. We reiterate our Buy rating and are raising our price target to $81."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Needham & Company

Add Your Comment